Form 8-K - Current report:
SEC Accession No. 0001193125-23-076684
Filing Date
2023-03-22
Accepted
2023-03-22 16:07:35
Documents
13
Period of Report
2023-03-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d395262d8k.htm   iXBRL 8-K 25878
2 EX-10.1 d395262dex101.htm EX-10.1 12053
  Complete submission text file 0001193125-23-076684.txt   166574

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA howl-20230316.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20230316_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20230316_pre.xml EX-101.PRE 11705
7 EXTRACTED XBRL INSTANCE DOCUMENT d395262d8k_htm.xml XML 3470
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 23752991
SIC: 2834 Pharmaceutical Preparations